menu

Loading...

FDMT Stock: Price, Forecast, Financials & AI Analysis

Loading chart...

High

9.740

Open

9.241

VWAP

9.34

Vol

1.53M

Mkt Cap

1.08B

Low

8.955

Amount

14.26M

EV/EBITDA(TTM)

--

Total Shares

--

EV

-129.19M

EV/OCF(TTM)

--

P/S(TTM)

10.02K

4D Molecular Therapeutics, Inc. is a late-stage biotechnology company advancing durable and disease-targeted therapeutics. The Company's lead product candidate 4D-150 is designed to be a backbone therapy forming the foundation of treatment of blinding retinal vascular diseases by providing multi-year sustained delivery of anti-VEGF (aflibercept and anti-VEGF-C) with a single, safe, intravitreal injection, which substantially reduces the treatment burden associated with current bolus injections. Its lead indication for 4D-150 is wet age-related macular degeneration, which is in Phase III development, and second indication is diabetic macular edema. The Company is developing 4D-710 for the treatment of a range of people with cystic fibrosis independent of their specific CFTR mutation. 4D-710 is an investigational genetic medicine candidate using the A101 vector for the treatment of cystic fibrosis lung disease. The Company's non-core programs include 4D-175, 4D-725, and 4D-310.

Show More

Events Timeline

(ET)

2026-02-09

08:30:00

4D Molecular Therapeutics Completes Enrollment for 4FRONT-1 Clinical Trial

2026-01-19 (ET)

2026-01-19

13:40:00

4D Molecular Therapeutics Grants 23,600 RSUs to New Employees

2026-01-07 (ET)

2026-01-07

08:20:00

4D Molecular Therapeutics Provides Corporate Update and Outlook for 2026

2025-12-17 (ET)

2025-12-17

07:10:00

4D Molecular Therapeutics Reports Positive Interim Data from 4D-710 Clinical Trial

2025-11-17 (ET)

2025-11-17

06:08:56

Kristian Humer Appointed CFO of 4D Molecular

2025-11-10 (ET)

2025-11-10

08:05:06

4D Molecular anticipates funding to last through the second half of 2028.

2025-11-10

08:04:25

4D Molecular Announces Q3 Earnings Per Share of $1.01, Exceeding Consensus Estimate of 98 Cents

News

Globenewswire

01-17Globenewswire

4D Molecular Therapeutics Grants 23,600 RSUs to New Employees

Benzinga

2025-12-19Benzinga

Major Stocks Including BlackBerry, FedEx, and Nike Decline in Friday's Pre-Market Trading

SeekingAlpha

2025-12-17SeekingAlpha

4D Molecular Shares Decline Following Initial Trial Results for Cystic Fibrosis Treatment

Globenewswire

2025-12-17Globenewswire

4D Molecular Therapeutics Reports Positive Interim Data for 4D-710 in Cystic Fibrosis Trial

NASDAQ.COM

2025-12-17NASDAQ.COM

4D Molecular Therapeutics Announces Encouraging Interim Phase 1 Results for 4D-710 in Cystic Fibrosis

Globenewswire

2025-12-12Globenewswire

4D Molecular Therapeutics Grants 13,800 RSUs to New Employees Under Inducement Plan

6 Analyst Rating

Wall Street analysts forecast FDMT stock price to rise

5 Buy

0 Hold

1 Sell

Moderate Buy

Current: 0.000

Low

17.00

Averages

29.40

High

38.00

Current: 0.000

Low

17.00

Averages

29.40

High

38.00

Barclays

initiated

$33

AI Analysis

2026-01-27

Reason

Barclays

Price Target

$33

AI Analysis

2026-01-27

initiated

Reason

Barclays assumed coverage of 4D Molecular with an Overweight rating and $33 price target. Barclays initiated coverage of 12 biotech stocks and assumed coverage of 11 with a positive view of the industry. The analyst likes the setup for the group in 2026. Many biotech stocks remain undervalued, the analyst tells investors in a research note. The firm expects continued mergers and acquisitions, "strong" underlying fundamentals, and less of a focus on drug pricing to act as "significant tailwinds."

RBC Capital

Lisa Walter

Outperform

maintain

$26 -> $32

2025-11-11

Reason

RBC Capital

Lisa Walter

Price Target

$26 -> $32

2025-11-11

maintain

Outperform

Reason

RBC Capital analyst Lisa Walter raised the firm's price target on 4D Molecular to $32 from $26 and keeps an Outperform rating on the shares after its Q3 results. The company's current cash position of $372M plus additional funds from the recent APAC deal with Otsuka and capital raise should extend the runway by 6 months into the second half of FY28 and fund both wAMD and DME pivotals, the analyst tells investors in a research note, adding that the recent funding "adds some cushion to the runway".

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for FDMT

Unlock Now

Valuation Metrics

The current forward P/E ratio for 4D Molecular Therapeutics Inc (FDMT.O) is -1.26, compared to its 5-year average forward P/E of -5.49. For a more detailed relative valuation and DCF analysis to assess 4D Molecular Therapeutics Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

N/A

5Y Average PE

-5.49

Current PE

-1.26

Overvalued PE

-2.34

Undervalued PE

-8.64

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

N/A

5Y Average EV/EBITDA

-2.79

Current EV/EBITDA

1.44

Overvalued EV/EBITDA

0.41

Undervalued EV/EBITDA

-5.99

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

5Y Average PS

119.64

Current PS

56.68

Overvalued PS

210.43

Undervalued PS

28.84

Financials

AI Analysis

Annual

Quarterly

Whales Holding FDMT

BVF Partners L.P.

RA Capital Management, L.P.

Novo Holdings A/S

Trading Trends

People Also Watch

Frequently Asked Questions

What is 4D Molecular Therapeutics Inc (FDMT) stock price today?

The current price of FDMT is 9.33 USD — it has decreased -3.42

What is 4D Molecular Therapeutics Inc (FDMT)'s business?

4D Molecular Therapeutics, Inc. is a late-stage biotechnology company advancing durable and disease-targeted therapeutics. The Company's lead product candidate 4D-150 is designed to be a backbone therapy forming the foundation of treatment of blinding retinal vascular diseases by providing multi-year sustained delivery of anti-VEGF (aflibercept and anti-VEGF-C) with a single, safe, intravitreal injection, which substantially reduces the treatment burden associated with current bolus injections. Its lead indication for 4D-150 is wet age-related macular degeneration, which is in Phase III development, and second indication is diabetic macular edema. The Company is developing 4D-710 for the treatment of a range of people with cystic fibrosis independent of their specific CFTR mutation. 4D-710 is an investigational genetic medicine candidate using the A101 vector for the treatment of cystic fibrosis lung disease. The Company's non-core programs include 4D-175, 4D-725, and 4D-310.

What is the price predicton of FDMT Stock?

Wall Street analysts forecast FDMT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for FDMT is29.40 USD with a low forecast of 17.00 USD and a high forecast of 38.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is 4D Molecular Therapeutics Inc (FDMT)'s revenue for the last quarter?

4D Molecular Therapeutics Inc revenue for the last quarter amounts to 14.00K USD, decreased -50.00

What is 4D Molecular Therapeutics Inc (FDMT)'s earnings per share (EPS) for the last quarter?

4D Molecular Therapeutics Inc. EPS for the last quarter amounts to -0.86 USD, increased 30.30

How many employees does 4D Molecular Therapeutics Inc (FDMT). have?

4D Molecular Therapeutics Inc (FDMT) has 227 emplpoyees as of March 02 2026.

What is 4D Molecular Therapeutics Inc (FDMT) market cap?

Today FDMT has the market capitalization of 1.08B USD.